ArticleSleep2010
Anti-Tribbles homolog 2 autoantibodies in Japanese patients with narcolepsy.
Article in Sleep, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 88 citations in OpenAlex.
- Narcolepsy is (not) an autoimmune disease.Nature reviews. Neurology · 2026Review
- Increased neutrophil-to-lymphocyte ratio as a possible marker to detect neuroinflammation in patients with narcolepsy type 1.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2025Article
- The Role of T Cells in the Pathogenesis of Narcolepsy Type 1: A Narrative Review.International journal of molecular sciences · 2024Review
- Cell-based vs enzyme-linked immunosorbent assay for detection of anti-Tribbles homolog 2 autoantibodies in Chinese patients with narcolepsy.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2024Article
- The immunopathogenesis of narcolepsy type 1.Nature reviews. Immunology · 2024Review
- Narcolepsy-A Neuropathological Obscure Sleep Disorder: A Narrative Review of Current Literature.Brain sciences · 2022Review
- Narcolepsy: a model interaction between immune system, nervous system, and sleep-wake regulation.Seminars in immunopathology · 2022Review
- Reviewing the Clinical Implications of Treating Narcolepsy as an Autoimmune Disorder.Nature and science of sleep · 2021Review
- Immunotherapy in Narcolepsy.Current treatment options in neurology · 2020Review
- CSF orexin-A levels after rituximab treatment in recent onset narcolepsy type 1.Neurology(R) neuroimmunology & neuroinflammation · 2019Article
- HLA-DQB1*06:02 allele frequency and clinic-polysomnographic features in Saudi Arabian patients with narcolepsy.Sleep & breathing = Schlaf & Atmung · 2019Article
- Genetics of narcolepsy.Human genome variation · 2019Review
- Article
- Autoimmunity in narcolepsy.Current opinion in pulmonary medicine · 2017Review
- Narcolepsy Type 1 as an Autoimmune Disorder: Evidence, and Implications for Pharmacological Treatment.CNS drugs · 2017Review
- Is it Time for Immunotherapy Trials in Narcolepsy?Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2017Article
- Intravenous Immunoglobulin Therapy in Pediatric Narcolepsy: A Nonrandomized, Open-Label, Controlled, Longitudinal Observational Study.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2017Observational
- Article
- The role of orexin in post-stroke inflammation, cognitive decline, and depression.Molecular brain · 2015Review
- Unmet needs of patients with narcolepsy: perspectives on emerging treatment options.Nature and science of sleep · 2015Review
Corrections and comments
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
STUDY
objectivesNarcolepsy is a sleep disorder characterized by excessive daytime sleepiness and cataplexy. The association with human leukocyte antigen (HLA)-DQB1*0602 and T-cell receptor alpha locus suggests that autoimmunity plays a role in narcolepsy. A recent study reported an increased prevalence of autoantibodies against Tribbles homolog 2 (TRIB2) in patients with narcolepsy. To replicate this finding, we examined anti-TRIB2 autoantibodies in Japanese patients with narcolepsy.
designWe examined anti-TRIB2 autoantibodies against a full-length [35S]-labeled TRIB2 antigen in Japanese patients with narcolepsy-cataplexy (n = 88), narcolepsy without cataplexy (n = 18), and idiopathic hypersomnia with long sleep time (n = 11). The results were compared to Japanese healthy controls (n = 87). Thirty-seven healthy control subjects were positive for HLA-DRB1*1501-DQB1*0602. We also examined autoantibodies against another Tribbles homolog, TRIB3, as an experimental control. MEASUREMENTS AND
resultsAutoantibodies against TRIB2 were found in 26.1% of patients with narcolepsy-cataplexy, a significantly higher prevalence than the 2.3% in healthy controls. We found that anti-TRIB3 autoantibodies were rare in patients with narcolepsy and showed no association with anti-TRIB2 indices. No significant correlation was found between anti-TRIB2 positivity and clinical information.
conclusionsWe confirmed the higher prevalence and specificity of anti-TRIB2 autoantibodies in Japanese patients with narcolepsy-cataplexy. This suggests a subgroup within narcolepsy-cataplexy might be affected by an anti-TRIB2 autoantibody-mediated autoimmune mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.